Flamel Technologies S.A. (ADR) Stock Nasdaq
Equities
US3384881096
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | - |
|
Jul. 01 | Avadel Pharmaceuticals plc(NasdaqGM:AVDL) added to Russell Small Cap Completeness Index | CI |
Jul. 01 | Avadel Pharmaceuticals plc(NasdaqGM:AVDL) added to Russell 2000 Index | CI |
Financials (USD)
Sales 2024 * | 168M | Sales 2025 * | 298M | Capitalization | 1.63B |
---|---|---|---|---|---|
Net income 2024 * | -48M | Net income 2025 * | 58M | EV / Sales 2024 * | 9.55 x |
Net cash position 2024 * | 19.66M | Net cash position 2025 * | 70.24M | EV / Sales 2025 * | 5.22 x |
P/E ratio 2024 * |
-30.6
x | P/E ratio 2025 * |
28.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.29% |
Latest transcript on Flamel Technologies S.A. (ADR)
Managers | Title | Age | Since |
---|---|---|---|
Gregory Divis
CEO | Chief Executive Officer | 57 | 17-01-02 |
Thomas McHugh
DFI | Director of Finance/CFO | 59 | 19-12-01 |
Scott Macke
COO | Chief Operating Officer | - | 14-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Eric Ende
BRD | Director/Board Member | 55 | 18-11-30 |
Gregory Divis
CEO | Chief Executive Officer | 57 | 17-01-02 |
Mark McCamish
BRD | Director/Board Member | 72 | 19-12-04 |
1st Jan change | Capi. | |
---|---|---|
+61.53% | 856B | |
+38.95% | 631B | |
-3.66% | 359B | |
+15.06% | 325B | |
+9.18% | 297B | |
+5.89% | 234B | |
+16.53% | 226B | |
+15.67% | 177B | |
+2.47% | 165B |